Experiments show promising results for a drug that could lead to a lasting treatment for millions of Americans with macular degeneration.
Researchers at the University of North Carolina School of Medicine today published new findings in the hunt for a better treatment for macular degeneration. In studies using mice, a class of drugs known as MDM2 inhibitors proved highly effective at regressing the abnormal blood vessels responsible for the vision loss associated with the disease.
“We believe we may have found an optimized treatment for macular degeneration,” said senior study author Sai Chavala, MD, director of the Laboratory for Retinal Rehabilitation and assistant professor of Ophthalmology and Cell Biology & Physiology at the UNC School of Medicine. “Our hope is that MDM2 inhibitors would reduce the treatment burden on both patients and physicians.”
The research appeared Sept. 9, 2013 in the Journal of Clinical Investigation.
As many as 11 million Americans have some form of macular degeneration, which is the most common cause of central vision loss in the western world. Those with the disease find many daily activities such as driving, reading and watching TV increasingly difficult.
Currently, the best available treatment for macular degeneration is an antibody called anti-VEGF that is injected into the eye. Patients must visit their doctor for a new injection every 4-8 weeks, adding up to significant time and cost.
“The idea is we’d like to have a long-lasting treatment so patients wouldn’t have to receive as many injections,” said Chavala. “That would reduce their overall risk of eye infections, and also potentially lower the economic burden of this condition by reducing treatment costs.” Chavala practices at the Kittner Eye Center at UNC Health Care in Chapel Hill and New Bern.
All patients with age-related macular degeneration start out with the “dry” form of the disease, which can cause blurred vision or blind spots. In about 20 percent of patients, the disease progresses to its “wet” form, in which abnormal blood vessels form in the eye and begin to leak fluid or blood, causing vision loss.
While anti-VEGF works by targeting the growth factors that lead to leaky blood vessels, MDM2 inhibitors target the abnormal blood vessels themselves causing them to regress — potentially leading to a lasting effect.
Chavala and his colleagues investigated the effects of MDM2 inhibitors in cell culture and in a mouse model of macular degeneration. They found that the drug abolishes the problematic blood vessels associated with wet macular degeneration by activating a protein known as p53. “p53 is a master regulator that determines if a cell lives or dies. By activating p53, we can initiate the cell death process in these abnormal blood vessels,” said Chavala.
The Latest Bing News on:
Macular degeneration
- Local group helps macular degeneration patients cope with vision losson April 26, 2024 at 3:07 am
To provide opportunity for encouragement, Phoenix-based Associated Retina Consultants, in coordination with the International Low Vision Support Group, has established a Macular Degeneration Support ...
- BCI maker Science acquires retinal implant from Pixium Visionon April 25, 2024 at 12:54 pm
Brain-computer interface developer Science Corporation acquired the IP and related assets for the Pixium Vision Prima implant.
- BrightFocus Foundation Announces $10M in New Funding Across Brain and Vision Research, Celebrates Historic Diversity of Grant Award Recipientson April 24, 2024 at 11:00 pm
Global nonprofit BrightFocus Foundation announces $10 million in new Alzheimer’s disease, macular degeneration, and glaucoma research grant funding—age-related diseases with no cure that affect more ...
- Over-the-counter eye drops safe to use with AMD medicationon April 24, 2024 at 10:30 pm
I am a healthy 67-year-old female being treated with Eylea for wet age-related macular degeneration (AMD). I have just had my second round of Eyelea, and with the pollen starting up, my eyes are ...
- High dose aflibercept may be promising for treatment of age-related macular degenerationon April 24, 2024 at 2:55 pm
Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events were comparable across treatment groups. Evidence Rating Level: 1 (Excellent) Study ...
- AMD STOPPER Offers New Hope to Sufferers of Age-Related Macular Degenerationon April 23, 2024 at 9:50 am
AMD Stopper Inc. is a newly organized company which holds the formulas, patent applications, and intellectual property rights to the formula developed by an eye care researcher to treat Age-Related ...
- Restoring sight is possible now with optogeneticson April 23, 2024 at 3:31 am
Several companies are experimenting with optogenetics to create a “bionic eye” that can restore sight in visually impaired people.
- Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034 | DelveInsighton April 22, 2024 at 2:31 pm
DelveInsight's Dry Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment practices, dry age-related macular degeneration marketed drug, ...
- Macular Degeneration vs. Glaucomaon April 18, 2024 at 5:00 pm
Both macular degeneration and glaucoma can lead to vision loss and blindness. But they have different causes and treatments. Age-related macular degeneration (AMD) and glaucoma are two of the most ...
The Latest Google Headlines on:
Macular degeneration
[google_news title=”” keyword=”Macular degeneration” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Macular degeneration treatment
- Local group helps macular degeneration patients cope with vision losson April 26, 2024 at 3:07 am
To provide opportunity for encouragement, Phoenix-based Associated Retina Consultants, in coordination with the International Low Vision Support Group, has established a Macular Degeneration Support ...
- BrightFocus Foundation Announces $10M in New Funding Across Brain and Vision Research, Celebrates Historic Diversity of Grant Award Recipientson April 24, 2024 at 11:00 pm
Pictured is BrightFocus Macular Degeneration Research grant recipient Yara Lechanteur ... and helps develop effective treatments and new drugs. BrightFocus funds international eye and brain research ...
- Over-the-counter eye drops safe to use with AMD medicationon April 24, 2024 at 10:30 pm
I am a healthy 67-year-old female being treated with Eylea for wet age-related macular degeneration (AMD). I have just had my second round of Eyelea, and with the pollen starting up, my eyes are ...
- High dose aflibercept may be promising for treatment of age-related macular degenerationon April 24, 2024 at 2:55 pm
Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events were comparable across treatment groups. Evidence Rating Level: 1 (Excellent) Study ...
- First in the GCC: Niner Pharmaceuticals Launches Innovative Eye Treatmenton April 23, 2024 at 10:52 am
Niner Pharmaceuticals Launches Innovative Eye TreatmentDubai, Dubai, United Arab Emirates - April 23, 2024 — Niner ...
- AMD STOPPER Offers New Hope to Sufferers of Age-Related Macular Degenerationon April 23, 2024 at 9:50 am
AMD Stopper Inc. is a newly organized company which holds the formulas, patent applications, and intellectual property rights to the formula developed by an eye care researcher to treat Age-Related ...
- Focus on Eyes: Sir Arthur Conan Doyle, Jules Stein started out as ophthalmologistson April 23, 2024 at 2:01 am
Most ophthalmologists focus on the management of eye diseases and performance of eye surgeries. Some achieve greatness outside the practice.
- Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034 | DelveInsighton April 22, 2024 at 2:31 pm
DelveInsight's Dry Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment practices, dry age-related macular degeneration marketed drug, ...
- Macular Degeneration vs. Glaucomaon April 18, 2024 at 5:00 pm
Both macular degeneration and glaucoma can lead to vision loss and blindness. But they have different causes and treatments. Age-related macular degeneration (AMD) and glaucoma are two of the most ...
- Wet vs. Dry Macular Degeneration: What Is the Difference?on April 14, 2024 at 5:00 pm
Learn more about the causes, types, and treatments for both types of age-related macular degeneration. AMD doesn’t cause total vision loss, but it can severely impair central vision in some people.
The Latest Google Headlines on:
Macular degeneration treatment
[google_news title=”” keyword=”macular degeneration treatment” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]